PL4321157T3 - Nowe zastosowanie kombinacji blokera receptora angiotensyny (arb) z inhibitorem neutralnej endopeptydazy (nepi) - Google Patents
Nowe zastosowanie kombinacji blokera receptora angiotensyny (arb) z inhibitorem neutralnej endopeptydazy (nepi)Info
- Publication number
- PL4321157T3 PL4321157T3 PL23202190.7T PL23202190T PL4321157T3 PL 4321157 T3 PL4321157 T3 PL 4321157T3 PL 23202190 T PL23202190 T PL 23202190T PL 4321157 T3 PL4321157 T3 PL 4321157T3
- Authority
- PL
- Poland
- Prior art keywords
- nepi
- arb
- combination
- receptor blocker
- new use
- Prior art date
Links
- 229940125364 angiotensin receptor blocker Drugs 0.000 title 1
- 239000002792 enkephalinase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/056680 WO2015030711A1 (en) | 2013-08-26 | 2013-08-26 | New use |
| US201461972933P | 2014-03-31 | 2014-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4321157T3 true PL4321157T3 (pl) | 2025-03-03 |
Family
ID=51494327
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23202190.7T PL4321157T3 (pl) | 2013-08-26 | 2014-08-26 | Nowe zastosowanie kombinacji blokera receptora angiotensyny (arb) z inhibitorem neutralnej endopeptydazy (nepi) |
| PL19202854.6T PL3626270T3 (pl) | 2013-08-26 | 2014-08-26 | Leczenie chorób sercowo-naczyniowych |
| PL14761702T PL3038654T3 (pl) | 2013-08-26 | 2014-08-26 | Nowe zastosowanie |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19202854.6T PL3626270T3 (pl) | 2013-08-26 | 2014-08-26 | Leczenie chorób sercowo-naczyniowych |
| PL14761702T PL3038654T3 (pl) | 2013-08-26 | 2014-08-26 | Nowe zastosowanie |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20160213646A1 (pl) |
| EP (4) | EP3038654B1 (pl) |
| JP (1) | JP6097888B2 (pl) |
| CY (1) | CY1122531T1 (pl) |
| DK (3) | DK3626270T3 (pl) |
| ES (3) | ES2767084T3 (pl) |
| FI (2) | FI4321157T3 (pl) |
| HR (3) | HRP20240034T1 (pl) |
| HU (3) | HUE069419T2 (pl) |
| LT (3) | LT3626270T (pl) |
| PL (3) | PL4321157T3 (pl) |
| PT (3) | PT3038654T (pl) |
| RS (3) | RS65037B1 (pl) |
| SI (3) | SI3626270T1 (pl) |
| SM (1) | SMT202500001T1 (pl) |
| WO (1) | WO2015028941A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3626270T3 (da) | 2013-08-26 | 2024-01-15 | Novartis Ag | Behandling af kardiovaskulære sygdomme |
| US10562866B2 (en) * | 2015-02-06 | 2020-02-18 | Mylan Laboratories Limited | Amorphous trisodium sacubitril valsartan and a process for the preparation thereof |
| PL4212152T3 (pl) | 2015-05-11 | 2025-08-11 | Novartis Ag | Schemat dawkowania sakubitrylu-walsartanu do leczenia przewlekłej skurczowej niewydolności serca |
| WO2016193883A1 (en) * | 2015-05-29 | 2016-12-08 | Novartis Ag | Sacubitril and valsartan for treating metabolic disease |
| CN106309388A (zh) * | 2015-06-30 | 2017-01-11 | 深圳信立泰药业股份有限公司 | 一种用于心衰治疗的药物组合物及其制备方法 |
| CN107510653A (zh) * | 2016-06-17 | 2017-12-26 | 常州爱诺新睿医药技术有限公司 | 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法 |
| WO2017036420A1 (zh) * | 2015-09-06 | 2017-03-09 | 常州方楠医药技术有限公司 | 含沙库比曲和缬沙坦的药用组合物及其制备方法 |
| CN106491600A (zh) * | 2015-09-06 | 2017-03-15 | 常州方楠医药技术有限公司 | 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
| WO2017042700A1 (en) * | 2015-09-07 | 2017-03-16 | Sun Pharmaceutical Industries Limited | Solid forms of valsartan and sacubitril |
| CN106580908A (zh) * | 2015-10-16 | 2017-04-26 | 深圳信立泰药业股份有限公司 | 一种用于心血管疾病治疗的口服制剂及其制备方法 |
| CN105330609B (zh) * | 2015-12-07 | 2017-12-22 | 南京正大天晴制药有限公司 | 一种制备lcz696的方法 |
| JP7156945B2 (ja) | 2016-02-03 | 2022-10-19 | ノバルティス アーゲー | 有機化合物のガレヌス製剤 |
| CN106176681A (zh) * | 2016-08-25 | 2016-12-07 | 泰力特医药(湖北)有限公司 | 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法 |
| WO2019008485A1 (en) * | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL |
| EP3840746A1 (en) * | 2018-08-23 | 2021-06-30 | Novartis AG | New pharmaceutical use for the treatment of heart failure |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| WO2021052441A1 (zh) | 2019-09-20 | 2021-03-25 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0443983B1 (de) | 1990-02-19 | 1996-02-28 | Ciba-Geigy Ag | Acylverbindungen |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| CN1249682A (zh) * | 1997-01-10 | 2000-04-05 | 麦克公司 | 用于治疗有症状的心力哀竭的血管紧张素ⅱ拮抗剂 |
| DE60315795T2 (de) * | 2002-01-17 | 2008-06-05 | Novartis Ag | Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren |
| MXPA05012299A (es) * | 2003-05-16 | 2006-01-30 | Novartis Ag | Composicion farmaceutica que comprende valsartan. |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| KR101589317B1 (ko) | 2007-11-06 | 2016-01-28 | 노파르티스 아게 | 안지오텐신 수용체 길항제/차단제 (arb) 및 중성 엔도펩티다제 (nep) 억제제의 초구조에 기초한 이중-작용 제약 조성물 |
| KR20180117734A (ko) | 2008-11-22 | 2018-10-29 | 제넨테크, 인크. | 유방암의 치료를 위한, 화학요법과 조합된 항-vegf 항체의 용도 |
| CN103079554A (zh) | 2010-08-24 | 2013-05-01 | 诺华有限公司 | 在接受抗凝血剂疗法的哺乳动物中治疗高血压和/或预防或治疗心力衰竭 |
| RU2667643C2 (ru) * | 2012-08-24 | 2018-09-21 | Новартис Аг | Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия |
| EP3038653A1 (en) * | 2013-08-26 | 2016-07-06 | Novartis AG | New use |
| DK3626270T3 (da) | 2013-08-26 | 2024-01-15 | Novartis Ag | Behandling af kardiovaskulære sygdomme |
-
2014
- 2014-08-26 DK DK19202854.6T patent/DK3626270T3/da active
- 2014-08-26 PL PL23202190.7T patent/PL4321157T3/pl unknown
- 2014-08-26 RS RS20240031A patent/RS65037B1/sr unknown
- 2014-08-26 HU HUE23202190A patent/HUE069419T2/hu unknown
- 2014-08-26 SM SM20250001T patent/SMT202500001T1/it unknown
- 2014-08-26 PL PL19202854.6T patent/PL3626270T3/pl unknown
- 2014-08-26 PT PT147617021T patent/PT3038654T/pt unknown
- 2014-08-26 HU HUE19202854A patent/HUE064634T2/hu unknown
- 2014-08-26 LT LTEP19202854.6T patent/LT3626270T/lt unknown
- 2014-08-26 PL PL14761702T patent/PL3038654T3/pl unknown
- 2014-08-26 EP EP14761702.1A patent/EP3038654B1/en not_active Revoked
- 2014-08-26 EP EP24206614.0A patent/EP4512397A3/en active Pending
- 2014-08-26 SI SI201432059T patent/SI3626270T1/sl unknown
- 2014-08-26 ES ES14761702T patent/ES2767084T3/es active Active
- 2014-08-26 EP EP23202190.7A patent/EP4321157B1/en active Active
- 2014-08-26 HR HRP20240034TT patent/HRP20240034T1/hr unknown
- 2014-08-26 HR HRP20241763TT patent/HRP20241763T1/hr unknown
- 2014-08-26 FI FIEP23202190.7T patent/FI4321157T3/fi active
- 2014-08-26 EP EP19202854.6A patent/EP3626270B1/en active Active
- 2014-08-26 HR HRP20200060TT patent/HRP20200060T1/hr unknown
- 2014-08-26 SI SI201431464T patent/SI3038654T1/sl unknown
- 2014-08-26 RS RS20200047A patent/RS59816B1/sr unknown
- 2014-08-26 WO PCT/IB2014/064074 patent/WO2015028941A1/en not_active Ceased
- 2014-08-26 DK DK14761702.1T patent/DK3038654T3/da active
- 2014-08-26 RS RS20241359A patent/RS66371B1/sr unknown
- 2014-08-26 ES ES19202854T patent/ES2968541T3/es active Active
- 2014-08-26 FI FIEP19202854.6T patent/FI3626270T3/fi active
- 2014-08-26 ES ES23202190T patent/ES3001196T3/es active Active
- 2014-08-26 PT PT232021907T patent/PT4321157T/pt unknown
- 2014-08-26 SI SI201432099T patent/SI4321157T1/sl unknown
- 2014-08-26 DK DK23202190.7T patent/DK4321157T3/da active
- 2014-08-26 LT LTEP23202190.7T patent/LT4321157T/lt unknown
- 2014-08-26 US US14/914,005 patent/US20160213646A1/en not_active Abandoned
- 2014-08-26 JP JP2016537414A patent/JP6097888B2/ja active Active
- 2014-08-26 PT PT192028546T patent/PT3626270T/pt unknown
- 2014-08-26 HU HUE14761702A patent/HUE047186T2/hu unknown
- 2014-08-26 LT LTEP14761702.1T patent/LT3038654T/lt unknown
-
2020
- 2020-01-28 CY CY20201100075T patent/CY1122531T1/el unknown
- 2020-11-24 US US17/103,327 patent/US20210077461A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI4321157T1 (sl) | Nova uporaba kombinacije blokatorja receptorja angiotenzina (arb) z nevtralnim zaviralcem endopeptidaze (nepi) | |
| EP2970340A4 (en) | BETA-Lactamase INHIBITORS | |
| EP2943204A4 (en) | BETA-Lactamase INHIBITORS | |
| EP2948450A4 (en) | METALLOENZYMINHIBITORVERBINDUNGEN | |
| ZA201506516B (en) | Hdac inhibitors | |
| PL2970272T3 (pl) | Inhibitory glikozydazowe | |
| ZA201702252B (en) | A selective inhibitor of prosphatidylinositol 3-kinase-gamma | |
| PL2984871T3 (pl) | Operacja pdcp w celu podwójnego połączenia | |
| PL3068685T3 (pl) | Przewłoka prowadząca elementu kotwicznego | |
| PT3293176T (pt) | Forma cristalina de um inibidor de pde4 | |
| PT2964616T (pt) | Inibidores da neprilisina | |
| GB201317609D0 (en) | Inhibitor compounds | |
| AP2015008621A0 (en) | Substituted bisphenyl butanoic nep 'neutral endopeptidase' inhibitors | |
| GB201300357D0 (en) | Plumbing diverter component | |
| IL240019A0 (en) | Estrogen receptor inhibitors | |
| GB201309426D0 (en) | Biomarkers | |
| EP3084587A4 (en) | Determining image rescale factors | |
| SMT202500023T1 (it) | Profarmaci di antagonisti di nmda | |
| GB201308077D0 (en) | Biomarkers | |
| GB201313664D0 (en) | Bcl-3 inhibitors | |
| IL245386A0 (en) | A crystalline beta-lactamase inhibitor | |
| SI3014029T1 (sl) | Sifonska enota | |
| SG11201509142UA (en) | Detecting endocrine disrupting compounds | |
| GB201321328D0 (en) | Inhibitor compounds | |
| GB201305503D0 (en) | Inhibitor |